$BSX · BOSTON SCIENTIFIC CORP
Boston Scientific reported Q3 2026 results: net sales of $5.138B (+1.5% YoY), GAAP EPS of $0.40 (down from $0.51), and adjusted EPS of $0.73 (down from $0.75). Operating income fell 21% YoY to $828M, hit by $81M in litigation charges and $63M in restructuring costs. The company guided Q4 2026 net sales to decline (3.0)% to (1.0)% and narrowed full-year adjusted EPS to $3.16–$3.18.
- Q3 GAAP net income fell to $582M from $755M YoY, with EPS dropping to $0.40 from $0.51.
- Adjusted EPS of $0.73 missed the prior-year $0.75, reflecting margin compression.
- Q3 operating income declined 21% YoY to $828M, pressured by $81M in litigation charges and $63M in restructuring costs.
- Q4 2026 guidance calls for net sales decline of (3.0)% to (1.0)% on a reported and organic basis.
- Full-year 2026 adjusted EPS guidance narrowed to $3.16–$3.18, implying Q4 adjusted EPS of $0.77–$0.79.
Extended-hours trading shows BSX at $44.23, down 1.84% vs the regular close of $45.06, reflecting negative reaction to the Q4 sales decline guidance and YoY earnings contraction.
A $65B medtech giant guiding for negative sales growth in Q4 after a cybersecurity incident and booking $157M in YTD litigation charges is a rare double-hit that demands investor attention.
MedSurg growth was anemic at 0.6% reported, with Urology declining 3.2% — a red flag in a sector where mid-single-digit growth is the norm for large-cap medtech. Neuromodulation (+13.1%) was the lone bright spot.
The August 2026 cybersecurity incident is cited as a material operational disruption; Q4 guidance for a (3.0)% to (1.0)% sales decline signals ongoing impact. Litigation-related charges of $81M in Q3 and $157M YTD represent a new and potentially recurring headwind.